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Although the MAP kinase-interacting kinases (MNKs) have been known for!15 years, their roles in the regulation of protein synthesis
have remained obscure. Here, we explore the involvement of theMNKs in brain-derived neurotrophic factor (BDNF)-stimulated protein
synthesis in cortical neurons frommice. Using a combination of pharmacological and genetic approaches, we show that BDNF-induced
upregulation of protein synthesis requires MEK/ERK signaling and the downstream kinase, MNK1, which phosphorylates eukaryotic
initiation factor (eIF) 4E. Translation initiation ismediated by the interaction of eIF4Ewith them7GTP cap ofmRNAandwith eIF4G. The
latter interaction is inhibited by the interactions of eIF4E with partner proteins, such as CYFIP1, which acts as a translational repressor.
We find that BDNF induces the release of CYFIP1 from eIF4E, and that this depends on MNK1. Finally, using a novel combination of
BONCAT and SILAC, we identify a subset of proteins whose synthesis is upregulated by BDNF signaling via MNK1 in neurons. Interest-
ingly, this subset of MNK1-sensitive proteins is enriched for functions involved in neurotransmission and synaptic plasticity. Addition-
ally, we find significant overlap between our subset of proteins whose synthesis is regulated by MNK1 and those encoded by known
FMRP-bindingmRNAs. Together, our data implicateMNK1 as a key component of BDNF-mediated translational regulation in neurons.
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Introduction
Regulation of mRNA translation is crucial in determining the
proteome (Schwanhausser et al., 2011). In neurons, regulating
gene expression at translation, rather than transcription, allows
localized control of synthesis of specific proteins at postsynaptic
sites, contributing to synaptic plasticity (Liu-Yesucevitz et al.,
2011).
Brain-derived neurotrophic factor (BDNF) is implicated in di-
verse neurological processes (Karpova, 2014; Panja and Bramham,
2014). Stimulation of neurons with BDNF increases overall protein
synthesis (Takei et al., 2001, 2004, 2009) and alters the neuronal
proteome (Liao et al., 2007; Spellman et al., 2008; Manadas et al.,
2009;Leal et al., 2014).Furthermore,BDNFactivates componentsof
the translational machinery via the MEK/ERK and mammalian
target-of-rapamycin, complex 1 (mTORC1) pathways (Takei et al.,
2001, 2004, 2009; Kanhema et al., 2006).
Eukaryotic initiation factor eIF4E binds the 5"-cap structure
(containing 7-methylGTP; m7GTP) of cytoplasmic mRNAs and
is crucial for their translation. eIF4E is regulated by themTORC1
and MEK/ERK pathways and brings additional proteins to the
mRNA to facilitate translation initiation. eIF4E is phosphory-
lated exclusively on Ser209 (Flynn and Proud, 1995) by the MAP
kinase-interacting kinases, MNKs (Fukunaga and Hunter, 1997;
Waskiewicz et al., 1997, 1999; Ueda et al., 2004).MNKs are phos-
phorylated and thus activated by MAP kinases, e.g., ERK (Fig.
1A). Mice express two MNKs, MNK1 and MNK2. MNK1 shows
low basal activity which increases following stimulation of ERK
signaling (Waskiewicz et al., 1999; Scheper et al., 2001), whereas
MNK2 shows high basal activity, independent of ERK signaling.
BDNF induces MNK1 phosphorylation (Takei et al., 2001) and a
MEK/ERK-dependent increase in phospho-eIF4E (Takei et al.,
2001; Schratt et al., 2004; Kanhema et al., 2006). Although they
are implicated in cell transformation/tumorigenesis, the MNKs’
physiological roles remain unclear (Joshi and Platanias, 2014).
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The availability of eIF4E to bind to eIF4G and initiate translation
is inhibited by its interaction with eIF4E-binding proteins, 4E-BPs,
of which the most abundant in brain is 4E-BP2 (Bidinosti et al.,
2010). 4E-BP2 is phosphorylated bymTORC1 (Fig. 1B). eIF4E also
interacts in a translationally repressive manner with cytoplasmic
fragile X mental retardation protein (FMRP)-interacting protein,
CYFIP1 (Napoli et al., 2008).CYFIP1bindsFMRP(Fig. 1C), a trans-
lational repressor protein which interacts with numerous mRNAs
involved in regulating synaptic function (Darnell and Klann, 2013).
In neuronal cells, BDNF causes release of CYFIP1 from eIF4E,
thereby regulating mRNA translation (Napoli et al., 2008).
Although the MNKs have been implicated in protein
synthesis-dependent synaptic plasticity (Panja et al., 2009, 2014),
their function in translational regulation remains obscure. Here,
we show that BDNF-induced stimulation of protein synthesis in
primary cortical neurons requires MEK/ERK signaling andMNK1.
Furthermore, MNK1 is necessary for BDNF-induced release of
CYFIP1 fromanm7GTP resin,which captures eIF4E and associated
proteins. Finally, using a novel combination of bio-orthogonal non-
canonical amino acid tagging (BONCAT;Dieterich et al., 2006) and
stable-isotope labeling in cell culture (SILAC; Huo et al., 2012), we
identify a subset of proteinswhose synthesis is regulatedbyBDNF in
an MNK1-dependent manner. Strikingly, many are encoded by
mRNAs that bind FMRP.
Materials andMethods
Animals
Animals used were C57Bl/6Jmice orMNK-WT,MNK1-KO (MNK1#/#
MNK2$/$), MNK2-KO (MNK1$/$ MNK2#/#), and MNK-DKO
(MNK1#/#MNK2#/#) mice of either gender that were kindly provided
by Dr Rikiro Fukunaga (Osaka University, Japan; Ueda et al., 2004).
Reagents
Triton X and Tween were obtained from Acros Organics. Ethylene-
diamine tetra-acetic acid (EDTA) and PBS were from Fisher Scientific.
Hank’s Balanced Salt Solution (HBSS), Neurobasal, B27 Supplement,
L-glutamine, penicillin/streptomycin were from Life Technologies. Pa-
pain was fromWorthington Biochemical. L-cysteine, bovine serum albu-
min (BSA), soybean trypsin inhibitor (STI), glycerol 2-phosphate
disodium salt hydrate (!-GP), sodium fluoride (NaF), dithiothreitol
(DTT), sodium metavanadate (NaVO3), and poly-D-lysine were ob-
tained from Sigma-Aldrich. Mycozap was from Lorne and ethylene gly-
col tetra-acetic acid (EGTA) was from Melford.
Primary cultures
Primary cultures of cortical neurons were isolated as previously de-
scribed (Wong et al., 2005). Cortices were isolated in ice-coldHBSS from
P0 or P1 mice. Tissue was gently broken up and digested in neurobasal
medium containing papain (20 U/ml) and L-cysteine (0.32 mg/ml) at
37°C for 20 min followed by 31°C for an additional 20 min. Tissue was
then washed once in a light inhibiting solution containing 1 mg/ml each
of BSA and STI then a heavy inhibiting solution containing 10 mg/ml
each of BSA and STI. The dissociated tissue was washed once and tritu-
ratedwith fire-polished glass pipettes. After anotherwash, cells were then
passed through a 40 "m cell strainer and 1.5–1.7% 106 cells were plated
onto poly-D-lysine-coated 35 mm culture dishes. After 1 h, overlying
mediumwas removed and replaced with neurobasal medium containing
2%B27 supplement, 0.5mM L-glutamine, and either 100U/ml penicillin/
streptomycin or 1%Mycozap.Half of themediumwas then changed and
replaced by fresh medium every 3–4 d before use at 10–12 DIV.
Treatment of neuronal cells
Primary cultures were treated with following drugs and concentrations:
BDNF (25 ng/ml, Alomone Labs), CGP57380 (50 "M, Sigma-Aldrich),
AZD6244 (10"M, Selleck Chemicals), rapamycin (100 nM,Millipore), or
MNK-I1 (0.1 "M, MRC-Technology). Inhibitors were added 30 min be-
fore BDNF treatment to allow sufficient time for them to enter the cells
and exert their effects.
Western blot
Cells were lysed on ice using lysis buffer (50mMTris-HCl, 50mM!-GP,1
mM EGTA, 1 mM EDTA, 1% Triton X, 10 mM NaF, 1 mM dithiothreitol,
0.5 mMNaVO3, 1% protease inhibitor cocktail; Roche). Cell lysates were
then centrifuged for 15min at 13,000% g and supernatants transferred to
new tubes and sample buffer was added to a final concentration of 1%
and samples boiled for 5min. Equal amounts of samples were separated on
a 12.5% polyacrylamide gel and then transferred to a nitrocellulose mem-
brane (0.45"mpore size) via electro-blotting. Membranes were blocked in
PBS containing 0.1%Tween (PBST) and 5% (w/v) BSA for 45min, washed
in PBST and then incubated with primary antibody in PBST containing 2%
(w/v) BSA for 1 h at room temperature or 4°C overnight. After washing,
membranes were incubated with appropriate secondary antibody for 1 h at
room temperature and imaged using the LI-COROdyssey infrared imaging
system.
The following antibodies fromCell Signaling Technology were used at
the indicated dilutions: eIF4E (9742), 1:1000; phospho-eIF4E (Ser209;
9741), 1:500; 4E-BP2 (2845) 1:1000; phospho-ERK1/2 (T202/204; 4370),
1:1000; p-PKB (T408; 4056), 1:1000; p-S6 (S240/244; 2215), 1:1000. An-
tibody for CYFIP, 1:500 (07–531) was from Millipore, total S6, 1:2000
(sc-74459) was from Santa Cruz Biotechnology, and GAPDH 1:500
(G8795) was from Sigma-Aldrich. Fluorescently tagged secondary anti-
bodies were from Fisher Scientific.
Immunoblotting data were quantified using LI-COR Odyssey software
(v3.0) and experimental treatments are expressed relative to untreated neu-
rons. Blots for p-eIF4E, CYFIP1, and 4E-BP2 were normalized to eIF4E
following enrichment using m7GTP beads. Blots for p-S6 were normalized
to S6, and blots for p-PKB and p-ERKwere normalized to GAPDH.
m7GTP pull-down assay
m7GTP sepharose 4B beads (7.5"l, GEHealthcare; dilutedwith 7.5"l of
sepharoseCL-4B beads, SigmaAldrich) or 20"l ofm7GTP agarose beads
(Jena Laboratories) were used. Before usage, the beadswerewashed twice
in ice-cold lysis buffer. Primary cortical neurons were lysed on ice using
lysis buffer. Cell lysates were then centrifuged for 15 min at 13,000 % g
and supernatant transferred to new tubes. Equal amounts of samples
were incubated with beads at 4°C for 120 min with rotation. The beads
were then washed twice with ice-cold lysis buffer. Bound proteins were
eluted with 20 "l 2% sample buffer followed by Western blotting.
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Figure 1. Signaling connections. A, BDNF stimulates ERK signaling, and thus MNK1 and
eIF4E phosphorylation, as well as mTORC1 and the phosphorylation of 4E-BP2. B, Phosphory-
lation of 4E-BP2 by mTORC1 leads to its dissociation from eIF4E, which can then bind other
partners. C, MNK1 phosphorylates eIF4E, and causes the dissociation of eIF4E from CYFIP1. It is
not clear whether phosphorylation of eIF4E itself regulates this interaction or whether MNK-
mediated phosphorylation of, e.g., CYFIP1, is also involved. Gray color indicates potential,
rather than established, links.
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[35S]methionine incorporation
10 "Ci [ 35S]methionine and 25 ng/ml BDNF were added to cells for 60
min before lysing in 1% sample buffer. Lysates were heated to 95°C for 5
min, vortexed and spun down at 13,000% g for 15 min before removing
the supernatant to a new tube. Five microliters of supernatant (in tripli-
cate) were added to filter paper, and boiled twice in 5% TCA for 1 min.
Filter papers were then washed once in 5% TCA and thereafter in 100%
ethanol before drying for 1–2 h. Quantification of the [ 35S]methionine
incorporation was performed using a Micro Plate counter 2450 Micro-
Beta 2 scintillation counter (PerkinElmer) with counting for 15min. Pro-
tein quantificationwas performed using the BCA assay (Fisher Scientific)
and samples were normalized to protein content. Cells treated with 10
"M cycloheximide (Fisher Scientific) were used as background.
Combined SILAC and AHA labeling
Primary cortical neurons were isolated and cultured as described above
except that the neurobasal was replaced with a Neurobasal SILAC me-
dium (Dundee Cell Products) containing either 89 mg/L heavy-arginine
( 13C6 $
15N4) and 154 mg/L heavy-lysine (
13C6 $
15N2), or 87 mg/L
medium-arginine ( 13C6) and 150 mg/L medium-lysine (
2H4). At 10–12
DIV cells were starved ofmethionine for 30min, then stimulated with 25
ng/ml of BDNF in the presence of 2 mM azidohomoalanine (AHA) for
2 h. Cells were washed twice in cold PBS and lysed in urea lysis buffer
(8 M urea, 300 mM Tris pH 8, 4% CHAPS, 1 M NaCI) containing a 2%
concentration of protease inhibitors (Roche). Lysates were then soni-
cated on ice and protein concentrations were determined using a 660
assay (Pierce). Equal amounts of protein frommediumandheavy labeled
neuronswere thenmixed before performing click-chemistry to an alkyne
agarose resin overnight with agitation at room temperature following the
manufacturer’s instructions (Life Technologies; C-10416). After incuba-
tion, the resin was washed once in H2O and resuspended in 1 ml of SDS
wash buffer (100 mM Tris, pH 8, 1% SDS, 250 mM NaCI, 5 mM EDTA)
with 10 mM DTT and incubated at 70°C for 15 min. The resin was then
centrifuged at 1000 % g for 5 min, supernatant discarded, and then
resuspended in SDSwash buffer with 40mM iodoacetamide for 30min in
the dark at room temperature.
The resin was then transferred to a spin column (Thermo Scientific,
89868) and washed eight times each with SDS wash buffer, urea wash
buffer (8 M urea/100 mM Tris, pH 8) and 20% acetonitrile followed by
three washes with 50 mM ammonium bicarbonate. After the last wash,
the resin was resuspended in 50mM ammoniumbicarbonate, transferred
to a fresh tube, and urea was added (&1.5 M final concentration). The
resin was centrifuged, supernatant removed, and 0.1 "g Lys-C (Roche)
protease was added and the resin incubated at 37°C for 4 hwith agitation.
Then calcium chloride (final concentration 0.1mM) and 1"g sequencing
grade trypsin (Promega) were added and the resin incubated at 37°C
overnight with agitation. The resin digest was then added to a spin col-
umn, centrifuged at 1000% g for 2 min, and the flow through was kept.
Formic acid was added (&1% final concentration) and samples were
stored at#80°C until used for mass spectrometry analysis.
Mass spectrometry analysis
Peptide mixtures were cleaned with 100 "l capacity C18 tips (Thermo
Scientific) with three incremental iterations from 2 to 98% HPLC grade
acetonitrile (Fisher Scientific), 0.1% analytical grade formic acid (Fisher
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Figure 2. BDNF stimulates global protein synthesis and increases the phosphorylation of
ERK, eIF4E, PKB, and S6. A, Cortical neurons were stimulated with BDNF for 60 min in the
presence of [ 35S]methionine; samples of lysate were then processed to measure the incorpo-
ration of radiolabel. An unpaired t test indicated an effect of BDNF on protein synthesis (t(16)'
3.3, p' 0.04); n' 9. B, C, Time courses for the effects of BDNF on eIF4E and ERK phosphory-
lation.Neuronswere stimulatedwithBDNF for 15, 30, 60, 90, 120, or 240min.One-wayANOVAs
revealed effects of stimulation-time on both phospho-eIF4E (F(6,71)' 2.764, p' 0.02) and
phospho-ERK (F(6,61)'11.8,p(0.001);n'9–11.D,E, The effect of BDNF stimulation for 30
min on phosphorylation of PKB and S6. There was an effect of BDNF on both phospho-PKB
(t(11)' 2.8, p' 0.02) and phospho-S6 (t(12)' 5.0 p( 0.001); n' 6; *p( 0.05 compared
with NT. Error bars represent SEM.
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Scientific). Eluates were lyophilized in a vacuum concentrator for 4 h at
room temperature (Eppendorf).
Lyophilized peptides were reconstituted in 30 "l of loading solution
(2% acetonitrile, 0.1% formic acid) and 7 "l were loaded by a Dionex
Ultimate 3000 (Thermo Scientific) at 20 "l/min for 6 min onto a C18
PepMap100 trapping cartridge (100 "m% 300 "m internal diameter, 5
"mparticle; Thermo Scientific). Peptides were eluted at 300 nl/min over
a gradient of 2–18% (355min), 18–35% (45min), and 35–85% (25min)
organic phase (95% acetonitrile, 5% DMSO (Sigma-Aldrich), 0.1% for-
mic acid) in aqueous phase (2% acetonitrile, 5% DMSO, 0.1% FA) and
resolved on anAcclaimPepMap100 column (C18, 75"m% 50 cm, 2"m
particle) retrofitted to a PicoTip nESI emitter (New Objective). Electro-
spray ionization was conducted at 2.4 kV and ions were characterized
with an Orbitrap Elite (Thermo Scientific) at 240,000 mass resolution.
The top 12$ 2 and$3 precursor ions per mass spectrometry (MS) scan
(minimum intensity 1000) were characterized by high-energy collisional
dissociation (HCD;30,000mass resolution, 1.2Da isolationwindow,40keV
collision energy) and collision-induceddissociation (CID; ion trapMS, 2Da
isolation window, 35 keV) with a dynamic exclusion ()5 ppm) of 200 s.
MS data processing. Peptide spectrum matching and quantifications
were performed with Proteome Discoverer 1.4 (Thermo Scientific) with
SequestHT against the UniprotKB SwissProt mouse proteome (down-
loaded 03/2014). For matching and quantitation, precursor tolerance
was set at 10 and 3 ppm, respectively. Fragment matching was set at 0.02
and 0.5 Da for HCD and CID, respectively. Target–decoy searching al-
lowed for 1 missed cleavage, a minimum length of 6 aa and a maximum
of three variable (1 equal) modifications of; Met-!Aha (M), deamida-
tion (Asn, Gln), or phosphorylation (Ser,Thr or Tyr). Carbamidomethyl
(Cys), was set as a fixed modifications with Lys ($4 Da), Arg ($6 Da), and
Lys ($8 Da), Arg ($10 Da) searched to determine medium and heavy la-
beled peptides, respectively. False discovery rate (FDR) was estimated with
the percolator. All three replicates were analyzed separately and opened in
unison (results were filtered at(5%peptide FDR) to enable parallel protein
groupingandquantitation.Thedatahavebeendeposited to theProteomeX-
change with identifier PXD001074 (Vizcaíno et al., 2013, 2014).
Statistical analysis
Western blot data from independent experimental replicates were ana-
lyzed using independent samples t tests, one-way ANOVAs, or two-way
ANOVAs as appropriate. Significant ANOVAs were followed up with
Dunnet’s t post hoc tests using untreated neurons as the control. Instances
of significant interactions or significance of bothmain effects from 3% 2
ANOVAs from experiments using neurons derived from MNK trans-
genic mice were also followed up with orthogonal linear contrasts (i.e., t
tests) within genotype. Significance was set to # ' 0.05. All statistical
analysis was done using SPSS, V.21 (IBM).
Results
BDNF stimulation of primary neurons elicited an increase in
protein synthesis, as assessed by measuring [35S]methionine in-
corporation (Fig. 2A). BDNF also caused a rapid increase in the
phosphorylation of eIF4E (Fig. 2B), a readout of MNK activity.
eIF4E phosphorylation was maximal after 30–60 min of BDNF
treatment (Fig. 2B), after which it declined almost to basal levels.
BDNF also caused rapid increases in the phosphorylation (activ-
ity) of ERK (Fig. 2C), which is upstream of MNK1, and in the
phosphorylation of protein kinase B (PKB) (Fig. 2D), and ribo-NT AZD6244 AZD6244
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Figure 3. Inhibition of MEK by AZD6244 blocks the BDNF-induced increases in eIF4E phos-
phorylation and global protein synthesis. A, Representative Western blots for the indicated
proteins or phosphoproteins. B–E, The effect of treating neurons with AZD6244 before BDNF
stimulation on the phosphorylation of eIF4E, ERK, PKB, and S6. Two-way (BDNF% AZD6244)
ANOVAs revealed main effects of BDNF on phospho-eIF4E (F(1,24)' 5.6, p' 0.026),phospho-
ERK (F(1,20)' 101.9, p( 0.001), phospho-PKB (F(1,16)' 29.6, p( 0.001), and phospho-S6
(F(1,16)' 15.5, p' 0.001), main effects of AZD6244 on phospho-eIF4E (F(1,24)' 28.8, p(
0.001), phospho-ERK (F(1,20)' 115.1, p( 0.001), and phospho-S6 (F(1,16)' 4.07, p' 0.05),
but not phospho-PKB ( p ' 0.2) and interactions between BDNF and AZD6244 on
4
phospho-eIF4E (F(1,24)' 13.1, p' 0.001) and phospho-ERK (F(1,20)' 86.8, p( 0.001) but
notphospho-PKB (p'0.47)orphospho-S6 (p'0.80);n'5–7.F, Neuronswere treatedwith
AZD6244 before BDNF stimulation in the presence of [ 35S]methionine, and samples were then
processed to measure incorporation of radiolabel. A two-way (BDNF% AZD6244) ANOVA re-
vealed a main effect of BDNF (F(1,43)' 4.7, p' 0.036), a main effect of AZD6244 (F(1,43)'
10.1,p'0.003), andan interactionbetweenBDNFandAZD6244administration (F(1,43)'5.6,
p' 0.023); n' 11–12; *p( 0.05 compared with NT. Error bars represent SEM.
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somal protein S6, a substrate for the S6 kinases which are acti-
vated by mTORC1 (Fig. 2E).
AZD6244 is a recently developed MEK inhibitor with greater
potency and specificity than UO126 and PD98059 (Yeh et al.,
2007), which have previously been used as MEK inhibitors.
AZD6244 completely inhibited the BDNF-induced phosphoryla-
tion of ERK and the increase in eIF4E phosphorylation (Fig. 3A–
C), showing that they are dependent on MEK/ERK signaling. In
contrast, BDNF still stimulated the phosphorylation of PKB in
the presence of AZD6244, showing that this effect is not depen-
dent onMEK (Fig. 3D). AZD6244 also reduced basal and BDNF-
stimulated S6 phosphorylation (Fig. 3A,E), consistent with
previous reports that MEK/ERK signaling can contribute to the
control of mTORC1 (Ma et al., 2005; Carriere et al., 2011; Fon-
seca et al., 2011). Finally, AZD6244 prevented the BDNF-induced
increase in overall rates of protein synthesis (Fig. 3F).
To assess whether the BDNF-induced increase in protein syn-
thesis required MNK activity, CGP57380, a widely used MNK
inhibitor (Tschopp et al., 2000), was applied to neurons before
stimulation with BDNF. CGP57380 decreased basal eIF4E
phosphorylation and prevented the BDNF-induced increase,
without affecting ERK phosphorylation (Fig. 4A–C). Further-
more, CGP57380 also prevented the BDNF-induced increase
in protein synthesis (Fig. 4D). This finding suggests that MNK
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activity plays a key role in the activation of protein synthesis by
BDNF.
Although CGP57380 is often used as a MNK inhibitor, it also
inhibits several other kinases at similar concentrations in vitro
(Bain et al., 2007). Thus, we used themore recently characterized
compound, MNK-I1, that is both more potent and has greater
specificity thanCGP57380 (J. Beggs, G.G. Jones, S. Tian, J. Xie, V.
Iadevaia, V. Jenei, G. Thomas, C.G. Proud, unpublished obser-
vations). As observed for CGP57380, MNK-I1 decreased basal
eIF4E phosphorylation and prevented the BDNF-induced in-
crease in eIF4E phosphorylation (Fig. 4E) without affecting ERK,
PKB, or mTORC1 signaling (Fig. 4E,G). MNK-I1 also pre-
vented the BDNF-induced increase in protein synthesis (Fig.
4H ).). Interestingly, we noticed a potential small decrease in
overall levels of eIF4E by the combined application of BDNF
and MNK-I1 (Fig. 4F; see also 6D,G), although we did not
consistently see this throughout our experiments (data not
shown). Although it is not altogether clear what might be
mediating this subtle decrease, it does not affect the interpre-
tation of the data as them7-GTP pull-downs are normalized to
total eIF4E levels.
The data obtained using pharmacological inhibitors indicated
that the MNKs are important in the BDNF-induced increase in
protein synthesis in neuronal cells. To study this further, without
the need to use such compounds and to examine potentially
unique contributions of MNK1 and MNK2 to the observed ef-
fects, we made use of cortical neurons derived fromWT, MNK1
KO, MNK2 KO, or MNK1/2 DKO mice (Ueda et al., 2004).
BDNF caused an increase in eIF4E phosphorylation in neurons
from WT or MNK2 KO mice, but not in cells from MNK1 KO
mice (Fig. 5A,B). As expected, no phosphorylation of eIF4E was
seen in cells from DKO animals (data not shown). The BDNF-
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induced increases in ERK, PKB, and S6 phosphorylationwere not
affected in either MNK1 or MNK2 KO neurons (Fig. 5A,C–E).
Interestingly, BDNF treatment resulted in a trend toward a de-
crease in eIF4E phosphorylation in neurons from MNK1 KO
mice (Fig. 5A,B) suggesting that BDNF may also stimulate a
negative regulator of eIF4E phosphorylation. Finally, the BDNF-
induced increase in overall rates of protein synthesis was ob-
served in neurons derived fromWT andMNK2 KOmice, but no
increase was seen in cells fromMNK1KOorMNK1/2DKOmice
(Fig. 5F).
Translation initiation can be regulated via alterations in the
binding of eIF4E with small 4E-binding phosphoproteins
(4E-BPs) that block its ability to bind to eIF4G (Gingras et al.,
1999). Furthermore, BDNF stimulation has been found to result
in both an increase in 4E-BP2 phosphorylation (Takei et al.,
2001), a mechanism that is important for the release of 4E-BP2
from eIF4E, and in a decrease in the binding of eIF4E with CY-
FIP1 (Napoli et al., 2008; De Rubeis et al., 2013). Using affinity
chromatography on immobilized m7GTP to isolate eIF4E and
associated proteins, we observed that BDNF caused a decrease in
the binding of 4E-BP2 and CYFIP1 to the m7GTP resin (Fig.
6A,B). BDNF-induced 4E-BP2 release was prevented by prior
incubation of neurons with rapamycin (Fig. 6C), an mTORC1
inhibitor, but this effectwas insensitive to inhibition of theMNKs
by MNK-I1 (Fig. 6D), and was intact in neurons derived from
WT, MNK1 KO or MNK2 KO mice (Fig. 6E).
In marked contrast, the BDNF-induced release of CYFIP1
from eIF4E was not prevented by prior incubation of neurons
with rapamycin (Fig. 6F), but was prevented by MNK-I1 (Fig.
6G). There was also an increase in CYFIP1 association with the
m7GTP-resin following administration of MNK-I1 alone (Fig.
6G). Interestingly, rapamycin alone, which results in an increase
in eIF4E phosphorylation (Fig. 6H), also resulted in the release of
CYFIP1 from the m7GTP-resin (Fig. 6F). BDNF also failed to
induce the release of CYFIP1 in neurons from MNK1 KO mice
(Fig. 6I), and higher basal levels of CYFIP1 bindingwere also seen
in MNK1-KO neurons (Fig. 6I). Together, the data suggest that
MNK1 is important for regulating the levels of association of
CYFIP1 with the m7GTP resin in response to BDNF. The release
of CYFIP1 from eIF4Emight reflect phosphorylation of eIF4E on
the MNK site, Ser209 (J. Beggs, G.G. Jones, S. Tian, J. Xie, V.
Iadevaia, V. Jenei, G. Thomas, C.G. Proud, unpublished obser-
vations), although, because both CYFIP1 and FRMP are phos-
phoproteins, it is possible that they are substrates for the MNKs
and this contributes to their release from eIF4E. Extensive further
work is needed to address this.
Identification of proteins whose synthesis is regulated
by MNK1
The data showing that MNK1 mediates the effects of BDNF on
overall protein synthesis and onCYFIP1/eIF4E binding raised the
question: doesMNK1 regulate general protein synthesis or does it
selectively alter the synthesis of specific proteins? To examine the
rapid changes in protein synthesis induced by BDNF, we com-
bined two complementary labeling techniques: BONCAT (Diet-
erich et al., 2006) and SILAC (Ong et al., 2002), a combination
that has previously been applied and validated in a cancer cell line
and T cells (Somasekharan et al., 2012; Howden et al., 2013), but
not previously used in primary neurons. Primary neurons de-
rived fromMNK1WT or KOmice were plated in SILAC neuro-
basal medium in which arginine and lysine were replaced with
medium or heavy stable isotope versions of the amino acids,
respectively. Neurons were then treated with BDNF and pulse
labeled for 2 h with AHA, a methionine analog that contains an
azide functional group. AHA incorporation allowed us to selec-
tively isolate and analyze the proteins synthesized in the presence
of BDNF only during this brief time window (Howden et al.,
2013).We only analyzed BDNF-treatedWT andMNK1KOneu-
rons to specifically determine the subset of proteins regulated by
BDNF in an MNK1-dependent manner.
The experiment was performed in triplicate, and 718 proteins
were identified in at least two of the three replicates (Fig. 7; a full
list of proteins and raw data are available at the ProteomeX-
change; ID: PXD001074). To determine whether specific biolog-
ical processes were regulated via changes in protein synthesis
mediated through BDNF stimulation of MNK1, we performed
gene ontology (GO) analysis using the DAVID (database for an-
notation, visualization, and integrated discovery) bioinformatics
tool (Huang et al., 2009), and using the 718 identified proteins as
background. Given that a variety of cutoffs for analyzing SILAC
data have been reported, we looked for consistency in GO analy-
sis using three cutoffs with increasing stringency: 1, 1.5, or 2 SD
above the median M/H ratio from the SILAC data which corre-
spond to 1.46, 1.78, and 2.18M/H ratios, and results in lists of 26,
56, and 113 proteins, respectively (Fig. 7A,B). The GO analysis
examining biological processes, molecular function, and cellular
components is consistent across the different thresholds in find-
ing that proteins involved in synaptic plasticity, neurotransmitter
release, and vesicular transport/exocytosis are selectively upregu-
lated by BDNF in an MNK1 dependent manner (Table 1).
Previous work has found that CYFIP1 interacts with FMRP,
which binds to and suppresses, the translation of FMRP target
mRNA (Napoli et al., 2008). Thus, given thatMNK1mediates the
BDNF-induced release of CYFIP1 from eIF4E (Fig. 6), we hy-
pothesized that there would be an enrichment in proteins en-
coded by FMRP target mRNAs among those proteins whose
synthesis is sensitive to genetic removal of MNK1. Using a list of
842 high-confidence FMRP targets (Darnell et al., 2011) we
found that 107 of these proteins overlappedwith the 718 proteins
identified in at least two of three replicates from our study (Fig.
7C). Of the 56 proteins above the 1.5 SD threshold (Fig. 7D,
diamonds), 26 were FMRP targets, which is 3.1-fold greater than
the 8.3 proteins that would be expected by chance ($(1)
2 ' 47.6,
p( 0.001). This enrichment was also present using a threshold of
either 2 SD ($(1)
2 ' 11.8, p ' 0.001) or 1 SD ($(1)
2 ' 33.6, p (
0.001).
Discussion
The present study provides the first evidence that theMNKs, and
in particular MNK1, are required for the activation of overall
protein synthesis in response to any physiological stimulus, in
this case BDNF. Importantly, our data also reveal that, both ba-
sally and in response to BDNF, MNK1 regulates the association
between eIF4E and CYFIP1. BDNF normally brings about the
release of CYFIP1 from eIF4E, but this effect is abrogated either
by treatment of neurons with a novel and specificMNK inhibitor
(MNK-I1) and in MNK1-KO neurons. This combined pharma-
cological and genetic evidence provides strong support for the
conclusion that MNKs control eIF4E-CYFIP1 binding. Finally,
using a novel combination of BONCAT and SILAC, we identify a
subset of proteins whose synthesis is upregulated by BDNF-
induced MNK1 signaling and that are involved in synaptic plas-
ticity and neurotransmitter release. This labeling approach has
the advantage that, unlike another recently developed method,
ribosome profiling (Ingolia et al., 2009), it provides information
on the rates of accumulation (synthesis) of specific proteins. The
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p' 0.05); n' 6; *p( 0.05 compared with NT;$p( 0.05, †p( 0.10 compared with NT within genotype. Error bars represent SEM.
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format we used earlier (Huo et al., 2012) suffered limitations,
relative to that technique, in terms of proteome coverage; how-
ever, by selectively isolating newly synthesized proteins, their im-
proved enrichment and in-depth bottom-up LC-MS analysis
using ultra-high performance 50 cmnanocapillary chromatogra-
phy over extended gradients to enhance tryptic peptide separa-
tion, thus enabled optimized ultra-high resolution MS analysis,
we have now substantially enhanced the depth of coverage and
also recover more peptides from each parent protein.
Given the established role for BDNF in a variety of neurophys-
iological phenomena, such as synaptic plasticity, memory, devel-
opment, and psychiatric disorders (Bekinschtein et al., 2014;
Karpova, 2014; Panja and Bramham, 2014), our data suggest that
MNK1 signaling may also be an important player in these pro-
cesses. In particular, our proteomic data andGOanalysis suggests
that MNK1 is an important mediator of the well known effect of
BDNF on neurotransmitter release (Kang and Schuman, 1995;
Takei et al., 1997; Li et al., 1998) and is consistent with the in-
volvement of the MNKs in synaptic plasticity (Panja et al., 2009,
2014). Furthermore, the involvement of BDNF in fragile X syn-
drome (FXS), which involves cognitive deficits, has been sug-
gested (Castre´n and Castre´n, 2014). Our data indicating that
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proteins whose synthesis is regulated by MNK1 are enriched for
FMRP targets imply that MNK1 may be an important mediator
of the involvement of BDNF in FXS. Together, these findings
suggest that exploring the involvement of theMNKs in the many
functions of BDNF is warranted.
The present study suggests that the BDNF/MEK/ERK signal-
ing axis provides a distinct mode of translation regulation in
addition to that provided by the BDNF/mTORC1 axis. Although
previous work has found the MEK/ERK pathway to be integral
formany of the effects of BDNF on translation (Takei et al., 2001;
Kelleher et al., 2004; Kanhema et al., 2006), distinguishing the
specific contribution ofMEK/ERK frommTORC1 is challenging
given that mTORC1 is positively regulated viaMEK/ERK in neu-
rons (Kelleher et al., 2004; Fig. 2E). By interferingwith theMNKs,
which are downstream from MEK/ERK and do not affect
mTORC1 signaling, we have uncovered distinct contributions of
these two BDNF signaling axes to translational control. BDNF-
stimulated MNK1 activation is necessary for the release of
CYFIP1, but not 4E-BP2, from a m7GTP cap analog, whereas
BDNF-to-mTORC1 signaling selectively alters 4E-BP2 binding
with no effect onCYFIP1.However, there does appear to be some
crosstalk at the level of the MNKs, as inhibition of mTORC1 by
rapamycin results in an increase in eIF4E phosphorylation, al-
though this effect has been largely suggested to depend on
MNK2, not MNK1 (Wang et al., 2007; Stead and Proud, 2013).
Furthermore, BDNF results in a decrease in eIF4E phosphoryla-
tion in MNK1-KO neurons, suggesting that in the absence of
MNK1 the negative regulation of eIF4E phosphorylation via the
mTORC1 pathway may predominate, whereas in WT neurons
the MNK1 pathway is dominant.
A variety of neurological disorders, such as autism and fragile
X syndrome, have been linked to the dysregulation of mRNA
translation (Kelleher and Bear, 2008; Darnell and Klann, 2013).
Deregulation of the eIF4E/CYFIP1/FMRPcomplex—by artificial
overexpression of eIF4E (Santini et al., 2013), mutations in the
promoter of the EIF4E gene (Neves-Pereira et al., 2009), deletion
of 4E-BP2 (Gkogkas et al., 2013), or alterations in FMRP expres-
sion (Darnell and Klann, 2013)—leads to autism-related disor-
ders. Furthermore, levels of BDNF and of ERK signaling, which
activatesMNK1, is elevated in humanpatients andmousemodels
with autism-related disorders, and may contribute to their
pathogenesis (Nelson et al., 2001; Kalkman, 2012; Yang et al.,
2013; Almeida et al., 2014; Taurines et al., 2014; Yin et al., 2014).
Our data implicateMNK1 in the effects of BDNF on both general
translation and the release of the translational repressor, CYFIP1,
binding to an m7GTP cap analog, suggests that MNK1 may also
be an important contributor to these diseases.
Several additional lines of evidence suggest that identifying
MNK1 as a key regulator of BDNF/MEK/ERK signaling and
CYFIP1/eIF4E interactionsmay have important clinical impli-
cations. Stimulation of metabotropic glutamate receptors
(mGluRs) results in elevated MNK1 and eIF4E phosphorylation
via the MEK/ERK pathway (Banko et al., 2006) and mGluR an-
tagonists appear to have considerable potential in treating autism
and FXS (Silverman et al., 2012; Pop et al., 2014) including the
reversal of elevated ERK phosphorylation (Seese et al., 2014).
Furthermore, CYFIP1)mice have numerous behavioral abnor-
malities and deficits in synaptic plasticity that can be reversed
using anmGluR antagonist (Bozdagi et al., 2012) andMNK1-KO
mice have been recently reported to have deficits in LTP (Panja et
al., 2014).TheMNK1-dependent release of CYFIP1 from eIF4E is
expected to derepress the translation of FMRP-bound mRNAs
(Napoli et al., 2008); consistent with this, our data reveal that
BDNF-induced synthesis of a set of these proteins is impaired in
MNK1-KO cells. These include proteins such as SNAP25, a num-
ber of kinesin-interacting proteins, neurexin, and MAPK1 (i.e.,
ERK1). CYFIP1 has also been implicated in maintenance of den-
dritic complexity (Pathania et al., 2014) and coordinating BDNF-
induced cytoskeletal remodeling (De Rubeis et al., 2013),
suggesting that MNK1 may also play an important role in regu-
lating CYFIP1 involvement in these processes as well.
It remains to be established whether the observed effects of
inhibiting BDNF-to-MNK1 signaling is solely a consequence of
the phosphorylation of eIF4E or also involves MNK-catalyzed
phosphorylation of other substrates; e.g., CYFIP1 or FMRP, both
of which are phosphoproteins (Narayanan et al., 2007, 2008).
KnownMNK substrates do include some RNA-binding proteins,
whose ability to bind the mRNA for tumor necrosis factor # was
respectively decreased and increased by MNK-catalyzed phos-
phorylation (HnRNPA1; Buxade´ et al., 2005) andPSF (Buxade´ et
Table 1. Gene ontology analysis
1 SD 1.5 SD 2 SD
GO description Fold enrichment p Fold enrichment p Fold enrichment p
Biological process
Regulation of synaptic plasticity 6.7 1.9E-03 13.0 1.3E-04 — —
Neurotransmitter transport 5.1 2.4E-03 9.8 9.1E-05 13.9 1.7E-03
Regulation of neurotransmitter levels 4.8 1.1E-02 9.3 8.3E-04 15.9 1.1E-03
Secretion by cell 4.3 2.3E-04 8.4 1.2E-06 10.0 8.2E-04
Exocytosis 4.2 1.9E-02 8.2 1.6E-03 10.4 2.8E-02
Molecular function
Syntaxin-1 binding 6.5 1.2E-02 12.5 1.7E-03 — —
SNARE binding 5.2 2.7E-02 10.0 4.1E-03 — —
Syntaxin binding 5.2 2.7E-02 10.0 4.1E-03 — —
Microtubule binding 4.1 2.6E-03 6.8 8.0E-04 — —
Sequence-specific DNA binding 3.5 1.6E-02 5.7 7.4E-03 — —
Cellular component
Synaptic vesicle — — 12.8 1.7E-02 28.8 3.1E-03
Cilium 4.0 2.3E-02 8.0 1.7E-03 — —
Synapse 2.9 3.2E-03 5.2 9.9E-05 6.6 4.5E-03
Coated vesicle 5.1 2.9E-02 5.1 3.5E-02 8.6 4.0E-02
Neuron projection 3.9 2.6E-08 4.9 5.0E-06 — —
Identification of top five gene ontologies enriched in BDNF-stimulatedMNK1WT overMNK1 KO neurons classified under biological processes, molecular function, and cellular component. Analysis was performed using DAVID (Huang et al.,
2009). Fold enrichment indicates theenrichmentof the specific GO classifications over thebackgroundof the718proteins identified in at least twoof three replicates using cut-offs fromFigure6A. Reportedp values are EASE/modified Fisher’s
exact p values calculated by DAVID.
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al., 2008). Thus, it remains to be determined whether the effects
of the MNKs on these proteins contribute to any of the effects
observed here. Nonetheless, we find a correlation between ma-
nipulations that affect eIF4E phosphorylation and consequent
binding of CYFIP1 to a m7GTP cap analog. For example, inhibi-
tion of mTORC1 by rapamycin resulted in an increase in eIF4E
phosphorylation, as has been previously reported (Stead and
Proud, 2013), and also a release of CYFIP1 from the m7GTP
resin, further supporting the hypothesis that eIF4E phosphoryla-
tion is important for mediating the interaction of CYFIP1 with
the m7GTP mRNA cap.
Although the MNKs were discovered!15 years ago, little has
been discovered regarding their physiological roles. Data from
MNKknock-outmice or animals where Ser209 in eIF4E has been
mutated to alanine (which cannot be phosphorylated) indicate
roles for the MNKs/eIF4E phosphorylation in tumorigenesis
(Wendel et al., 2007; Furic et al., 2010; Ueda et al., 2010). How-
ever, eIF4Ephosphorylation did not affect overall protein synthe-
sis rates. Ours, and other recently published data (Panja et al.,
2014), now show that the MNKs play a key role in regulating
neuronal cell protein synthesis, including synthesis of proteins
encoded by mRNAs that bind FMRP. Given the importance of
new protein synthesis in synaptic plasticity and of BDNF and
FMRP in neurologic disorders, it is likely the MNKs play a key
role in normal and abnormal neuronal cell function. It will be im-
portant to learn more of the roles of the MNKs in neurologic pro-
cesses including learning, memory and other aspects of behavior.
Notes
Supplemental material for this article is available at http://www.ebi.ac.
uk/pride/archive/projects/PXD001074. The mass spectrometry pro-
teomics data have been deposited to the ProteomeXchange Consortium
(Vizcaíno et al., 2014) via the PRIDE partner repository with the dataset
identifier PXD001074. This material has not been peer reviewed.
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